Clinical Trial Update: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy [Phase 2]

View source ↗

Summary

Phase II single-arm exploratory study evaluating pemigatinib in advanced gastrointestinal cancer with FGFR alterations after standard therapy failure (excluding…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Gastrointestinal Cancer | Phase 2 | Status: UNKNOWN